{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:40:08Z","timestamp":1787316008814,"version":"build-2736575974"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T00:00:00Z","timestamp":1635897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Good Publication Practice"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>ACHILLES aimed to demonstrate efficacy of secukinumab on Achilles\u2019 tendon enthesitis in spondyloarthritis (SpA) patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients \u226518\u2009years (n\u2009=\u2009204) with active PsA or axial SpA and heel enthesitis were randomized 1:1 to secukinumab 150\/300\u2009mg or placebo up to week 24, and thereafter placebo patients were switched to secukinumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At week 24, a higher, yet statistically non-significant (P\u2009=\u20090.136), proportion of patients in secukinumab vs placebo reported resolution of Achilles tendon enthesitis in affected foot (42.2% vs 31.4%; odds ratio [OR]\u2009=\u20091.63; 95% CI: 0.87, 3.08). Proportion of patients reporting resolution of enthesitis based on Leeds Enthesitis Index was higher with secukinumab vs placebo (33.3% vs 23.5%; OR\u2009=\u20091.65; 95% CI: 0.85, 3.25) at week 24. Mean change from baseline in heel pain at week 24 was higher in secukinumab patients vs placebo (\u22122.8 [3.0] vs \u22121.9 [2.7]). Greater improvements with secukinumab were observed in heel enthesopathy activity and global assessment of disease activity. Imaging evaluation by local reading confirmed heel enthesitis on MRI at screening for all patients. Based on central reading, 56% presented with bone marrow oedema and\/or tendinitis; according to Heel Enthesitis MRI Scoring System (HEMRIS) post hoc analysis, 76% had signs of entheseal inflammation while 86% had entheseal inflammation and\/or structural changes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A substantial proportion of patients showed no signs of inflammation on the centrally read MRIs despite a clinical diagnosis of heel enthesitis, thus highlighting that the discrepancy between the clinical and imaging assessments of enthesitis requires further investigation. Although ACHILLES did not meet the primary end point, the study reported clinically meaningful improvements in patient-related outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>clinicaltrials.gov, NCT02771210<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab784","type":"journal-article","created":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T15:12:06Z","timestamp":1635520326000},"page":"2856-2866","source":"Crossref","is-referenced-by-count":26,"title":["Efficacy and safety of secukinumab in patients with spondyloarthritis and enthesitis at the Achilles tendon: results from a phase 3b trial"],"prefix":"10.1093","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8750-7186","authenticated-orcid":false,"given":"Frank","family":"Behrens","sequence":"first","affiliation":[{"name":"CIRI\/Rheumatology and Fraunhofer Institute for Translationale Medicine & Pharmacology (ITMP) and Cluster of Excellence Immune-Mediated Diseases (CIMD), Goethe-University , Frankfurt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8465-6207","authenticated-orcid":false,"given":"Philipp","family":"Sewerin","sequence":"additional","affiliation":[{"name":"Department of Rheumatology & Hiller Research Unit, University Hospital Duesseldorf , Duesseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5146-1964","authenticated-orcid":false,"given":"Eugenio","family":"de Miguel","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Hospital Universitario La Paz , Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf","family":"Patel","sequence":"additional","affiliation":[{"name":"Hull University Teaching Hospitals , Hull, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8857-0574","authenticated-orcid":false,"given":"Anastas","family":"Batalov","sequence":"additional","affiliation":[{"name":"Medical University of Plovdiv, University Hospital Kaspela , Plovdiv, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Dokoupilova","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Department of Pharmaceutical Technology, Medical Plus, s.r.o., Uherske Hradiste; Masaryk University , Brno, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Kleinmond","sequence":"additional","affiliation":[{"name":"ClinProject GmbH , Eurasburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Effie","family":"Pournara","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG , Basel, Basel-Stadt, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankita","family":"Shekhawat","sequence":"additional","affiliation":[{"name":"Novartis Healthcare Pvt. Ltd , Hyderabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Jentzsch","sequence":"additional","affiliation":[{"name":"Novartis Pharma GmbH , N\u00fcrnberg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Wiedon","sequence":"additional","affiliation":[{"name":"Novartis Pharma GmbH , N\u00fcrnberg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9475-9362","authenticated-orcid":false,"given":"Xenofon","family":"Baraliakos","sequence":"additional","affiliation":[{"name":"Rheumazentrum Ruhrgebiet-Ruhr-University Bochum , Herne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the ACHILLES study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,11,3]]},"reference":[{"key":"2022070614080179200_keab784-B1","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrrheum.2017.188","article-title":"Enthesitis: from pathophysiology to treatment","volume":"13","author":"Schett","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"2022070614080179200_keab784-B2","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.jbspin.2003.10.010","article-title":"Spondyloarthropathy with entheseal pain. A prospective study in 33 patients","volume":"71","author":"Godfrin","year":"2004","journal-title":"Joint Bone Spine"},{"key":"2022070614080179200_keab784-B3","first-page":"137","article-title":"Early psoriatic arthritis: the clinical spectrum","volume":"35","author":"Scarpa","year":"2008","journal-title":"J Rheumatol"},{"key":"2022070614080179200_keab784-B4","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s13075-016-1093-z","article-title":"Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis","volume":"18","author":"de Winter","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2022070614080179200_keab784-B5","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.38140","article-title":"Tumor necrosis factor \u03b1 inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort","volume":"65","author":"Ciurea","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2022070614080179200_keab784-B6","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.reuma.2017.03.010","article-title":"Heel pain in psoriatic arthropathy: analysis of a series of 291 patients","volume":"14","author":"Morales Ivorra","year":"2018","journal-title":"Reumatol Clin"},{"key":"2022070614080179200_keab784-B7","first-page":"473","article-title":"Best practice and research","volume":"20","author":"D'Agostino","year":"2006","journal-title":"Clin Rheumatol"},{"key":"2022070614080179200_keab784-B8","first-page":"487","article-title":"Heel pain in spondyloarthritis: results of a cross-sectional study of 275 patients","volume":"30","author":"Koumakis","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"2022070614080179200_keab784-B9","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0278-5919(03)00094-2","article-title":"Heel pain-plantar fasciitis and Achilles enthesopathy","volume":"23","author":"Williams","year":"2004","journal-title":"Clin Sports Med"},{"key":"2022070614080179200_keab784-B10","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.3899\/jrheum.180792","article-title":"Association between enthesitis and health-related quality of life in psoriatic arthritis in biologic-naive patients from 2 phase III ustekinumab trials","volume":"46","author":"McInnes","year":"2019","journal-title":"J Rheumatol"},{"key":"2022070614080179200_keab784-B11","doi-asserted-by":"crossref","first-page":"651","DOI":"10.3109\/14397595.2013.850182","article-title":"Correlations among enthesitis, clinical, radiographic and quality of life parameters in patients with ankylosing spondylitis","volume":"24","author":"Rezvani","year":"2014","journal-title":"Mod Rheumatol"},{"key":"2022070614080179200_keab784-B12","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00296-019-04480-9","article-title":"Enthesitis and its relationship with disease activity, functional status, and quality of life in psoriatic arthritis: a multi-center study","volume":"40","author":"Sunar","year":"2020","journal-title":"Rheumatol Int"},{"key":"2022070614080179200_keab784-B13","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s00296-007-0315-8","article-title":"Quality of life in patients with ankylosing spondylitis: a pilot study","volume":"27","author":"Turan","year":"2007","journal-title":"Rheumatol Int"},{"key":"2022070614080179200_keab784-B14","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s13075-019-2055-z","article-title":"Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies","volume":"21","author":"Coates","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2022070614080179200_keab784-B15","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/acr.23233","article-title":"Secukinumab and sustained improvement in signs and symptoms of patients with active ankylosing spondylitis through two years: results from a phase III study","volume":"69","author":"Marzo-Ortega","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2022070614080179200_keab784-B16","first-page":"890","article-title":"Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study","volume":"77","author":"Mease","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2022070614080179200_keab784-B17","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1093\/rheumatology\/kex301","article-title":"Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study","volume":"56","author":"McInnes","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2022070614080179200_keab784-B18","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"New Engl J Med"},{"key":"2022070614080179200_keab784-B19","doi-asserted-by":"crossref","first-page":"e001005","DOI":"10.1136\/rmdopen-2019-001005","article-title":"Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study","volume":"5","author":"Baraliakos","year":"2019","journal-title":"RMD Open"},{"key":"2022070614080179200_keab784-B20","doi-asserted-by":"crossref","first-page":"e339","DOI":"10.1016\/S2665-9913(20)30066-7","article-title":"5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial","volume":"2","author":"Marzo-Ortega","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2022070614080179200_keab784-B21","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/art.41477","article-title":"Secukinumab improves signs and symptoms of non-radiographic axial spondyloarthritis: primary results of a randomized controlled phase III study","volume":"73","author":"Deodhar","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2022070614080179200_keab784-B22","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1136\/ard.2009.121533","article-title":"A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial","volume":"69","author":"Dougados","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2022070614080179200_keab784-B23","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"2022070614080179200_keab784-B24","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1186\/s12891-020-03775-4","article-title":"Achilles tendon enthesitis evaluated by MRI assessments in patients with axial spondyloarthritis and psoriatic arthritis: a report of the methodology of the ACHILLES trial","volume":"21","author":"Baraliakos","year":"2020","journal-title":"BMC Musculoskelet Disord"},{"key":"2022070614080179200_keab784-B25","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.3899\/jrheum.181093","article-title":"The OMERACT MRI in enthesitis initiative: definitions of key pathologies, suggested MRI sequences, and a novel heel enthesitis scoring system","volume":"46","author":"Mathew","year":"2019","journal-title":"J Rheumatol"},{"key":"2022070614080179200_keab784-B26","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/pst.267","article-title":"Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches","volume":"7","author":"Lane","year":"2008","journal-title":"Pharm Stat"},{"key":"2022070614080179200_keab784-B27","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1002\/acr.20577","article-title":"Measures of psoriatic arthritis: tender and swollen joint assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander\/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI)","volume":"63(Suppl 11","author":"Mease","year":"2011","journal-title":"Arthritis Care Res"},{"key":"2022070614080179200_keab784-B28","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3899\/jrheum.160387","article-title":"Performance of 3 enthesitis indices in patients with peripheral spondyloarthritis during treatment with adalimumab","volume":"44","author":"Mease","year":"2017","journal-title":"J Rheumatol"},{"key":"2022070614080179200_keab784-B29","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40744-018-0123-5","article-title":"Efficacy and safety of secukinumab 150 mg with and without loading regimen in ankylosing spondylitis: 104-week results from MEASURE 4 study","volume":"5","author":"Kivitz","year":"2018","journal-title":"Rheumatol Ther"},{"key":"2022070614080179200_keab784-B30","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s10067-014-2524-3","article-title":"Metabolic syndrome associated to non-inflammatory Achilles enthesopathy","volume":"33","author":"Abate","year":"2014","journal-title":"Clin Rheumatol"},{"key":"2022070614080179200_keab784-B31","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/j.1365-2702.2005.01121.x","article-title":"Pain: a review of three commonly used pain rating scales","volume":"14","author":"Williamson","year":"2005","journal-title":"J Clin Nurs"},{"key":"2022070614080179200_keab784-B32","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.3899\/jrheum.141440","article-title":"Optimal strategies for reporting pain in clinical trials and systematic reviews: recommendations from an OMERACT 12 workshop","volume":"42","author":"Busse","year":"2015","journal-title":"J Rheumatol"},{"key":"2022070614080179200_keab784-B33","doi-asserted-by":"crossref","first-page":"241","DOI":"10.32098\/mltj.02.2016.12","article-title":"Assessment of enthesitis in patients with psoriatic arthritis using clinical examination and ultrasound","volume":"6","author":"Kristensen","year":"2016","journal-title":"Muscles Ligaments Tendons J"},{"key":"2022070614080179200_keab784-B34","first-page":"873","article-title":"FRI0380 Secukinumab provides sustained improvement of enthesitis in patients with ankylosing spondylitis: pooled analysis of four pivotal phase 3 studies","volume":"78","author":"Schett","year":"2019","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab784\/41174263\/keab784.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/7\/2856\/44473086\/keab784.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/7\/2856\/44473086\/keab784.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T10:11:48Z","timestamp":1657102308000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/7\/2856\/6420214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,3]]},"references-count":34,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,11,3]]},"published-print":{"date-parts":[[2022,7,6]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab784","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7,1]]},"published":{"date-parts":[[2021,11,3]]}}}